Zobrazeno 1 - 10
of 56
pro vyhledávání: '"M. Lipponen"'
Autor:
Reetta A. E. Eriksson, Tiina Nieminen, Lionel Galibert, Sanna K. Peltola, Petra Tikkanen, Piia Käyhty, Hanna M. Leinonen, Igor Oruetxebarria, Saana Lepola, Anniina J. Valkama, Eevi M. Lipponen, Hanna P. Lesch, Seppo Ylä-Herttuala, Kari J. Airenne
Publikováno v:
Frontiers in Medicine, Vol 10 (2023)
Externí odkaz:
https://doaj.org/article/577226a018c4442398fc2f758afd0a1c
Autor:
Reetta A. E. Eriksson, Tiina Nieminen, Lionel Galibert, Sanna K. Peltola, Petra Tikkanen, Piia Käyhty, Hanna M. Leinonen, Igor Oruetxebarria, Saana Lepola, Anniina J. Valkama, Eevi M. Lipponen, Hanna P. Lesch, Seppo Ylä-Herttuala, Kari J. Airenne
Publikováno v:
Frontiers in Medicine, Vol 9 (2022)
Gene therapy would greatly benefit from a method to regulate therapeutic gene expression temporally. Riboswitches are small RNA elements that have been studied for their potential use in turning transgene expression on or off by ligand binding. We co
Externí odkaz:
https://doaj.org/article/bac6cbe4bcff4b7981f043f3a2f22c28
Autor:
Anniina J. Valkama, Igor Oruetxebarria, Eevi M. Lipponen, Hanna M. Leinonen, Piia Käyhty, Heidi Hynynen, Vesa Turkki, Joonas Malinen, Tuukka Miinalainen, Tommi Heikura, Nigel R. Parker, Seppo Ylä-Herttuala, Hanna P. Lesch
Publikováno v:
Molecular Therapy: Methods & Clinical Development, Vol 17, Iss , Pp 717-730 (2020)
The interest in lentiviral vectors (LVs) has increased prominently for gene therapy applications, but few have reached the later stages of clinical trials. The main challenge has remained in scaling up the manufacturing process for the fragile vector
Externí odkaz:
https://doaj.org/article/7677766b879b48a5baadae07e874d057
Autor:
Hanna M. Leinonen, Eevi M. Lipponen, Anniina J. Valkama, Heidi Hynynen, Igor Oruetxebarria, Vesa Turkki, Venla Olsson, Jere Kurkipuro, Haritha Samaranayake, Ann-Marie Määttä, Nigel R. Parker, Seppo Ylä-Herttuala, Hanna P. Lesch
Publikováno v:
Molecular Therapy: Methods & Clinical Development, Vol 15, Iss , Pp 63-71 (2019)
The therapeutic efficacy of a lentiviral vector (LV) expressing the herpes simplex virus thymidine kinase (HSV-TK) was studied in an immunocompetent rat glioblastoma model. Intraperitoneal ganciclovir injections (50 mg/kg/day) were administered for 1
Externí odkaz:
https://doaj.org/article/58e30f80fca14c09842389d436188547
Since the late 1800s, the source selection – surface water or groundwater – for urban water supply has faced several policy changes in Finland. First, groundwater was favored. In 1920, driven by cost and reliability issues, one major city turned
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::33c4af054e2866eb4e6794bd00f41f97
https://trepo.tuni.fi/handle/10024/141288
https://trepo.tuni.fi/handle/10024/141288
Autor:
Eevi M. Lipponen, Tommi Heikura, Igor Oruetxebarria, Vesa Turkki, Piia Käyhty, Heidi Hynynen, Joonas Malinen, Anniina J. Valkama, Tuukka Miinalainen, Hanna Leinonen, Hanna P. Lesch, Seppo Ylä-Herttuala, Nigel Parker
Publikováno v:
Molecular Therapy. Methods & Clinical Development
Molecular Therapy: Methods & Clinical Development, Vol 17, Iss, Pp 717-730 (2020)
Molecular Therapy: Methods & Clinical Development, Vol 17, Iss, Pp 717-730 (2020)
The interest in lentiviral vectors (LVs) has increased prominently for gene therapy applications, but few have reached the later stages of clinical trials. The main challenge has remained in scaling up the manufacturing process for the fragile vector
Autor:
Hanna Leinonen, Seppo Ylä-Herttuala, Nigel Parker, Tiina Koponen, Tommi Heikura, Saana Lepola, Hanna P. Lesch, Eevi M. Lipponen
Publikováno v:
Human Gene Therapy
We have previously produced viral vectors (lentiviral vector, adenoviral vector, and adeno-associated viral vector) in small and in commercial scale in adherent cells using Pall fixed-bed iCELLis® bioreactor. Recently, a company called Univercells h
Autor:
Heidi Hynynen, Haritha Samaranayake, Ann-Marie Määttä, Jere Kurkipuro, Hanna Leinonen, Anniina J. Valkama, Nigel Parker, Venla Olsson, Seppo Ylä-Herttuala, Hanna P. Lesch, Vesa Turkki, Eevi M. Lipponen, Igor Oruetxebarria
Publikováno v:
Molecular Therapy: Methods & Clinical Development, Vol 15, Iss, Pp 63-71 (2019)
Molecular Therapy. Methods & Clinical Development
Molecular Therapy. Methods & Clinical Development
The therapeutic efficacy of a lentiviral vector (LV) expressing the herpes simplex virus thymidine kinase (HSV-TK) was studied in an immunocompetent rat glioblastoma model. Intraperitoneal ganciclovir injections (50 mg/kg/day) were administered for 1
The development and implementation of artificial intelligence (AI) applications in health care contexts is a concurrent research and management question. Especially for hospitals, the expectations regarding improved efficiency and effectiveness by th
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=od______2127::5366a0831032dbc715da7a85adee4a83
https://pergamos.lib.uoa.gr/uoa/dl/object/uoadl:2984847
https://pergamos.lib.uoa.gr/uoa/dl/object/uoadl:2984847
Autor:
Hanna P. Lesch, Tommi Heikura, Turkki, Eevi M. Lipponen, Seppo Ylä-Herttuala, Hanna Leinonen, Joonas Malinen, Anniina J. Valkama
Publikováno v:
Gene Therapy
Lentiviral vectors (LVs) are promising tools for gene therapy. However, scaling up the production methods of LVs in order to produce high-quality vectors for clinical purposes has proven to be difficult. In this article, we present a scalable and eff